An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
Loading...
Embargo End Date
Authors
Patel, R
Barker, HE
Kyula, J
McLaughlin, M
Dillon, MT
Schick, U
Hafsi, H
Thompson, A
Khoo, V
Harrington, K
Zaidi, S
Barker, HE
Kyula, J
McLaughlin, M
Dillon, MT
Schick, U
Hafsi, H
Thompson, A
Khoo, V
Harrington, K
Zaidi, S
Document Type
Journal Article
Date
2017-03
Date Accepted
2016-12-22
Abstract
Purpose Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, their clinical progress has been hampered by low bioavailability and off-target toxicities.Materials and methods We characterized the radiosensitizing activity of CCT244747, the first orally bioavailable Chk1 inhibitor. We used a panel of bladder and head and neck cancer cell lines and monitored the effect of combining CCT244747 with radiation both in in vitro and in vivo models.Results CCT244747 sensitized cancer cell lines to radiation in vitro and resulted in a growth delay in cancer xenograft models associated with a survival benefit. Radiosensitization was elicited by abrogation of the radiation-induced G2 arrest and premature entry into mitosis.Conclusions CCT244747 is a potent and specific Chk1 inhibitor that can be administered orally. It radiosensitizes tumour cell lines and represents a new therapy for clinical application in combination with radiotherapy.
Citation
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017, 122 (3), pp. 470 - 475
Source Title
Publisher
ISSN
0167-8140
eISSN
1879-0887
Research Team
Targeted Therapy